HC Wainwright Issues Pessimistic Forecast for Corcept Therapeutics (NASDAQ:CORT) Stock Price

Corcept Therapeutics (NASDAQ:CORT) had its price objective reduced by equities research analysts at HC Wainwright from $67.00 to $60.00 in a report issued on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s target price indicates a potential upside of 55.72% from the company’s previous close.

CORT has been the subject of several other research reports. Weiss Ratings reiterated a “hold (c)” rating on shares of Corcept Therapeutics in a research report on Monday, December 29th. Zacks Research lowered shares of Corcept Therapeutics from a “hold” rating to a “strong sell” rating in a report on Tuesday, January 13th. Wolfe Research cut shares of Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $30.00 price objective on the stock. in a research note on Wednesday, December 31st. Canaccord Genuity Group lifted their target price on shares of Corcept Therapeutics from $99.00 to $100.00 and gave the stock a “buy” rating in a report on Friday, January 23rd. Finally, Truist Financial set a $50.00 target price on shares of Corcept Therapeutics in a research report on Wednesday, December 31st. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Corcept Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $77.67.

Corcept Therapeutics Trading Down 4.8%

Shares of CORT opened at $38.53 on Wednesday. The stock’s fifty day simple moving average is $37.47 and its 200-day simple moving average is $61.00. The firm has a market capitalization of $4.10 billion, a PE ratio of 46.99 and a beta of 0.29. Corcept Therapeutics has a 12-month low of $28.66 and a 12-month high of $117.33. The company has a quick ratio of 2.85, a current ratio of 2.92 and a debt-to-equity ratio of 0.01.

Corcept Therapeutics (NASDAQ:CORT) last announced its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $0.20 EPS for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.13). Corcept Therapeutics had a return on equity of 15.19% and a net margin of 12.96%.The firm had revenue of $202.13 million during the quarter, compared to analyst estimates of $254.94 million. During the same quarter in the previous year, the business earned $0.26 earnings per share. Corcept Therapeutics’s revenue for the quarter was up 11.1% compared to the same quarter last year. As a group, research analysts predict that Corcept Therapeutics will post 1.36 earnings per share for the current year.

Insider Activity

In other Corcept Therapeutics news, insider William Guyer sold 20,000 shares of the business’s stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $40.87, for a total value of $817,400.00. Following the completion of the transaction, the insider directly owned 1,235 shares of the company’s stock, valued at approximately $50,474.45. The trade was a 94.18% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director G Leonard Baker, Jr. purchased 100,000 shares of the stock in a transaction on Tuesday, March 17th. The stock was acquired at an average price of $33.14 per share, with a total value of $3,314,000.00. Following the completion of the acquisition, the director directly owned 1,146,631 shares of the company’s stock, valued at approximately $37,999,351.34. This represents a 9.55% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders have sold 60,000 shares of company stock worth $2,241,035. Corporate insiders own 20.80% of the company’s stock.

Institutional Trading of Corcept Therapeutics

A number of large investors have recently bought and sold shares of CORT. Pathstone Holdings LLC lifted its stake in Corcept Therapeutics by 0.8% in the third quarter. Pathstone Holdings LLC now owns 18,013 shares of the biotechnology company’s stock valued at $1,497,000 after buying an additional 144 shares in the last quarter. Campbell Newman Asset Management Inc. increased its position in shares of Corcept Therapeutics by 0.5% during the third quarter. Campbell Newman Asset Management Inc. now owns 35,530 shares of the biotechnology company’s stock worth $2,953,000 after acquiring an additional 170 shares in the last quarter. Clearstead Advisors LLC raised its holdings in shares of Corcept Therapeutics by 163.6% during the third quarter. Clearstead Advisors LLC now owns 311 shares of the biotechnology company’s stock worth $26,000 after acquiring an additional 193 shares during the period. Gould Capital LLC raised its holdings in shares of Corcept Therapeutics by 50.0% during the third quarter. Gould Capital LLC now owns 600 shares of the biotechnology company’s stock worth $50,000 after acquiring an additional 200 shares during the period. Finally, Advisors Asset Management Inc. lifted its position in Corcept Therapeutics by 1.3% in the 2nd quarter. Advisors Asset Management Inc. now owns 18,935 shares of the biotechnology company’s stock valued at $1,390,000 after acquiring an additional 237 shares in the last quarter. 93.61% of the stock is owned by institutional investors.

Corcept Therapeutics News Roundup

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: FDA approval of Lifyorli (relacorilant) plus nab‑paclitaxel — the regulatory win is the primary commercial catalyst and triggered the recent multi‑day rally due to survival benefit data and earlier‑than‑expected decision. FDA Approves (BusinessWire)
• Positive Sentiment: Analyst/firm support: multiple firms raised or reiterated positive views (Truist to “strong‑buy”, Canaccord price target increase reported, HC Wainwright kept a Buy rating), which supports upside potential as the market prices in Lifyorli’s commercial opportunity. Analyst Coverage (Benzinga)
• Positive Sentiment: Insider confidence signal: market commentary highlighted a mid‑March purchase by a director (~100,000 shares) that likely helped amplify bullish positioning ahead of the approval. Insider Buy Analysis (QuiverQuant)
• Neutral Sentiment: Market structure/volatility: trading was temporarily halted (LULD pause) and the name has posted very large intraday moves as investors re‑price the company; expect elevated volume and short‑term volatility. Market Reaction Coverage (Reuters)
• Negative Sentiment: Multiple securities‑class‑action firms have filed/issued alerts alleging misstatements tied to prior FDA issues and patent litigation — several firms are seeking lead plaintiffs and note an April 21, 2026 deadline; these suits create tangible legal and financial overhang. Hagens Berman Alert (GlobeNewswire)
• Negative Sentiment: Recent insider selling: Corcept disclosed a sale by William Guyer (11,767 shares on Mar 20), which may be viewed negatively by some investors despite offsetting director purchases. Insider Sale SEC Filing

Corcept Therapeutics Company Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.